Clinical Trial Update: Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Andamertinib with or without platinum-doublet chemotherapy versus platinum-doublet chemotherapy in patients with Non-Small Cell Lung Ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Andamertinib (Andamertinib)

Snippet

Sponsor: Avistone Biotechnology Co., Ltd. | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: RECRUITING